Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Watch the video interviews from Heart Failure 2017 & World Congress on Acute Heart Failure
Take home messages: heart failure and iron
Take home messages on cardio-oncology
Highlights from the Young Investigators: Basic Science
Take home messages from the scientific programme chair
Take home messages from HFA President
Insights from Editor in Chief, EJHF: Top tips to get your papers accepted
Cardiopoietic Stem Cell Therapy Improved Left Ventricular Remodeling: CHART-1
The HeartLogic multi-sensor algorithm as a predictor of HF events: MultiSENSE
Heart Failure Guidelines - What has changed since 2016?
Adherence to guideline recommendations for life saving HF treatment: QUALIFY
Ivabradine in heart failure with preserved ejection fraction: EDIFY
Empagliflozin decreases risk of kidney function decline in T2D: EMPA-REG OUTCOME
Heart failure with mid ejection fraction in CHARM: the entire EF spectrum
The Grand Debate: Neprilysin inhibitor - LCZ 696 (Sacubitril/Valsartan)
The Grand Debate: Neprilysin inhibitor - Vasodilators in acute heart failure
Heart Failure Guidelines 2016 - Impact on my practice one year on
RELAX-AHF-2 Serelaxin in acute heart failure
Effects of Ularitide on clinical course and CV mortality: deep-dive of TRUE-AHF
Baseline BP and long term outcomes with TRV027: an analysis of BLAST-AHF
Bromocriptine for the treatment of peripartum cardiomyopathy
HFA News 2016 covered the highlights in the form of short videos focused on 6 main topics, with interviews from major presentations of the congress.
HFA News is sponsored by Novartis Pharma AG. This content has in no way been influenced by the sponsor.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved